Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck.

Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck.

Int J Dermatol. 2017 Mar 01;:

Authors: Villavicencio M, Granados-García M, Vilajosana E, Domínguez-Cherit J

Abstract
The objective of this review is to report to the medical community the most recent knowledge on prevention and management of dermatitis with the use of cetuximab simultaneously with radiotherapy in the treatment of squamous cell carcinomas of the head and neck. A review was conducted in PubMed of English language publications between 2010 and 2015. The search employed the terms 'skin toxicity', 'radiodermatitis', 'cetuximab', 'radiotherapy', and 'head and neck cancer'. Data related to the classification and management of dermatitis, associated with cetuximab with concomitant radiotherapy (n = 22), were critically reviewed. We conclude that dermatitis associated with bioradiotherapy is a predictable, treatable, and reversible event that does not affect administration of therapy or its clinical outcome when treated appropriately.

PMID: 28247918 [PubMed - as supplied by publisher]

http://ift.tt/2lCuN5I